Although there are currently known treatments for AIDS patients, the virus is still evolving, which means that it is not always possible to eradicate it from an infected organism. The FDA approved in November 2017 the first, complete treatment regimen containing two drugs: dolutegravir and rilpivirine (Juluca). The following article discusses current knowledge about a new, innovative drug as well as future therapeutic options of HIV-1 patients. The preparation can be used as a complete treatment regimen for HIV-1 infection to replace the current antiretroviral regimen in adults who have been virologically inhibited for at least 6 months. Clinical studies of this preparation show that the drug is well tolerated, is metabolizable and offers additional benefits, such as improving the lipid profile, improving bone mineral density and reduced bone resorption. Undoubtedly, longer observation of the effects of this drug therapy is needed, but this dual scheme seems to be a promising strategy for patients infected with HIV.
Support the magazine and subscribe to the content
This is premium stuff. Subscribe to read the entire article.